Literature DB >> 35069028

Medical Therapy in Chronic Refractory Ulcerative Colitis: When Enough Is Enough.

Aderson Omar Mourão Cintra Damião1, Natália Sousa Freitas Queiroz1.   

Abstract

Despite significant improvements in the management of ulcerative colitis (UC) in parallel with the evolution of therapeutic targets and novel biologics and small molecules, a subset of medically refractory patients still requires colectomy. Recent population-based studies demonstrate a trend toward a decrease in the rates of surgery for UC patients in the biological era, although the potential of disease modification with these agents is still debated. As the concept of irreversible bowel damage is underexplored in UC, refractory patients can be exposed to multiple treatments losing optimal timing for surgery and further developing complications such as dysplasia/cancer, dysmotility, microcolon, and other functional abnormalities. This review aims to discuss the concept of disease progression in UC, explore the limitations of medical treatment in refractory UC patients, and propose the application of a three-step algorithm that allows timely indication for surgery in clinical practice. Thieme. All rights reserved.

Entities:  

Keywords:  biologics; colectomy; tofacitinib; ulcerative colitis

Year:  2022        PMID: 35069028      PMCID: PMC8763462          DOI: 10.1055/s-0041-1740036

Source DB:  PubMed          Journal:  Clin Colon Rectal Surg        ISSN: 1530-9681


  63 in total

Review 1.  Ulcerative colitis as a progressive disease: the forgotten evidence.

Authors:  Joana Torres; Vincent Billioud; David B Sachar; Laurent Peyrin-Biroulet; Jean-Frédéric Colombel
Journal:  Inflamm Bowel Dis       Date:  2011-12-11       Impact factor: 5.325

2.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis.

Authors:  William J Sandborn; Gert van Assche; Walter Reinisch; Jean-Frederic Colombel; Geert D'Haens; Douglas C Wolf; Martina Kron; Mary Beth Tighe; Andreas Lazar; Roopal B Thakkar
Journal:  Gastroenterology       Date:  2011-11-04       Impact factor: 22.682

3.  Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Authors:  Bruce E Sands; Laurent Peyrin-Biroulet; Edward V Loftus; Silvio Danese; Jean-Frédéric Colombel; Murat Törüner; Laimas Jonaitis; Brihad Abhyankar; Jingjing Chen; Raquel Rogers; Richard A Lirio; Jeffrey D Bornstein; Stefan Schreiber
Journal:  N Engl J Med       Date:  2019-09-26       Impact factor: 91.245

4.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Authors:  Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Journal:  Gut       Date:  2011-01-05       Impact factor: 23.059

5.  There is Significant Practice Pattern Variability in the Management of the Hospitalized Ulcerative Colitis Patient at a Tertiary Care and IBD Referral Center.

Authors:  Shailja C Shah; Steven Naymagon; Benjamin L Cohen; Bruce E Sands; Marla C Dubinsky
Journal:  J Clin Gastroenterol       Date:  2018-04       Impact factor: 3.062

6.  Epidemiology and natural history of inflammatory bowel diseases.

Authors:  Jacques Cosnes; Corinne Gower-Rousseau; Philippe Seksik; Antoine Cortot
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

7.  AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.

Authors:  Joseph D Feuerstein; Kim L Isaacs; Yecheskel Schneider; Shazia Mehmood Siddique; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2020-01-13       Impact factor: 22.682

8.  Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.

Authors:  Hans Herfarth; Edward L Barnes; John F Valentine; John Hanson; Peter D R Higgins; Kim L Isaacs; Susan Jackson; Mark T Osterman; Kristen Anton; Anastasia Ivanova; Millie D Long; Christopher Martin; Robert S Sandler; Bincy Abraham; Raymond K Cross; Gerald Dryden; Monika Fischer; William Harlan; Campbell Levy; Robert McCabe; Steven Polyak; Sumona Saha; Emmanuelle Williams; Vijay Yajnik; Jose Serrano; Bruce E Sands; James D Lewis
Journal:  Gastroenterology       Date:  2018-06-30       Impact factor: 22.682

9.  Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk.

Authors:  M D Rutter; B P Saunders; K H Wilkinson; S Rumbles; G Schofield; M A Kamm; C B Williams; A B Price; I C Talbot; A Forbes
Journal:  Gut       Date:  2004-12       Impact factor: 23.059

10.  A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review.

Authors:  Ryan Ungaro; Jean-Frédéric Colombel; Trevor Lissoos; Laurent Peyrin-Biroulet
Journal:  Am J Gastroenterol       Date:  2019-06       Impact factor: 10.864

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.